Prostate

• 

  Publication Venue For

  • Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. 2021
  • Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy..  80:1244-1252. 2020
  • Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer..  79:1752-1761. 2019
  • E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer..  79:1226-1237. 2019
  • Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer..  79:1106-1116. 2019
  • DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations..  79:657-666. 2019
  • Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer..  79:604-613. 2019
  • HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer..  79:414-424. 2019
  • SRRM4 gene expression correlates with neuroendocrine prostate cancer..  79:96-104. 2019
  • Germline mutations in PPFIBP2 are associated with lethal prostate cancer..  78:1222-1228. 2018
  • A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer..  78:607-615. 2018
  • Rare germline mutations in African American men diagnosed with early-onset prostate cancer..  78:321-326. 2018
  • Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer..  78:266-277. 2018
  • Genetic factors influencing prostate cancer risk in Norwegian men..  78:186-192. 2018
  • Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients..  78:17-24. 2018
  • Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model..  77:446-457. 2017
  • Is PSA related to serum cholesterol and does the relationship differ between black and white men?.  75:1877-1885. 2015
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate..  75:1447-1453. 2015
  • Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America..  75:836-844. 2015
  • Carbohydrate intake, glycemic index and prostate cancer risk..  75:430-439. 2015
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats..  75:381-389. 2015
  • Patient preferences for treatments to delay bone metastases..  74:1488-1497. 2014
  • Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways..  73:754-762. 2013
  • The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model..  73:449-454. 2013
  • PDEF in prostate cancer..  72:592-596. 2012
  • Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences..  72:173-180. 2012
  • Emerging treatment options for patients with castration-resistant prostate cancer..  72:338-349. 2012
  • Racial differences in prostate cancer risk remain among US servicemen with equal access to care..  70:727-734. 2010
  • Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients..  69:520-527. 2009
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy..  68:1380-1386. 2008
  • ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells..  68:1273-1282. 2008
  • Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. 2017